BDBM50112245 CHEMBL3608741::US10030025, Compound 11::US10836768, Cpd no 11::US11731974, Compound 11::US9422299, 11::US9987274, Compound 11

SMILES Cc1nsc(n1)-c1nnc2[C@@H](CCO)N(CCn12)C(=O)c1ccc(F)cc1

InChI Key InChIKey=SZEYAOKHLPDWFZ-CYBMUJFWSA-N

Data  18 KI  13 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 17 hits for monomerid = 50112245   

TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50112245(CHEMBL3608741 | US10030025, Compound 11 | US108367...)
Affinity DataKi:  32nMAssay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist3 H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50112245(CHEMBL3608741 | US10030025, Compound 11 | US108367...)
Affinity DataKi:  32nMAssay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist3 H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50112245(CHEMBL3608741 | US10030025, Compound 11 | US108367...)
Affinity DataKi:  32nMAssay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50112245(CHEMBL3608741 | US10030025, Compound 11 | US108367...)
Affinity DataKi:  32nMAssay Description:Human NK-3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50112245(CHEMBL3608741 | US10030025, Compound 11 | US108367...)
Affinity DataKi:  32nMpH: 7.4Assay Description:The affinity of compounds of the invention for the human NK-3 receptor was determined by measuring the ability of compounds of the invention to compe...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSubstance-P receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50112245(CHEMBL3608741 | US10030025, Compound 11 | US108367...)
Affinity DataKi:  2.20E+4nMAssay Description:The affinity of compounds of the invention for the NK-1 receptor was evaluated in CHO recombinant cells which express the human NK-1 receptor. Membra...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSubstance-P receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50112245(CHEMBL3608741 | US10030025, Compound 11 | US108367...)
Affinity DataKi:  2.20E+4nMAssay Description:Human NK-1: The affinity of compounds of the invention for the NK-1 receptor was evaluated in CHO recombinant cells which express the human NK-1 rece...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSubstance-P receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50112245(CHEMBL3608741 | US10030025, Compound 11 | US108367...)
Affinity DataKi:  2.20E+4nM ΔG°:  -6.35kcal/molepH: 7.4 T: 2°CAssay Description:The affinity of compounds of the invention for the NK-1 receptor was evaluated in CHO recombinant cells which express the human NK-1 receptor. Membra...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSubstance-P receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50112245(CHEMBL3608741 | US10030025, Compound 11 | US108367...)
Affinity DataKi:  2.20E+4nMAssay Description:The affinity of compounds of the invention for the NK-1 receptor was evaluated in CHO recombinant cells which express the human NK-1 receptor. Membra...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSubstance-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50112245(CHEMBL3608741 | US10030025, Compound 11 | US108367...)
Affinity DataKi: >3.00E+4nMAssay Description:Human NK-2 The affinity of compounds of the invention for the NK-2 receptor was evaluated in CHO recombinant cells which express the human NK-2 recep...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSubstance-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50112245(CHEMBL3608741 | US10030025, Compound 11 | US108367...)
Affinity DataKi: >3.00E+4nMAssay Description:The affinity of compounds of the invention for the NK-2 receptor was evaluated in CHO recombinant cells which express the human NK-2 receptor. Membra...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSubstance-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50112245(CHEMBL3608741 | US10030025, Compound 11 | US108367...)
Affinity DataKi: >3.00E+4nM ΔG°: >-6.17kcal/molepH: 7.4 T: 2°CAssay Description:The affinity of compounds of the invention for the NK-2 receptor was evaluated in CHO recombinant cells which express the human NK-2 receptor. Membra...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSubstance-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50112245(CHEMBL3608741 | US10030025, Compound 11 | US108367...)
Affinity DataKi: >3.00E+4nMAssay Description:The affinity of compounds of the invention for the NK-2 receptor was evaluated in CHO recombinant cells which express the human NK-2 receptor. Membra...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50112245(CHEMBL3608741 | US10030025, Compound 11 | US108367...)
Affinity DataIC50:  73nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50112245(CHEMBL3608741 | US10030025, Compound 11 | US108367...)
Affinity DataIC50:  5.00E+4nMAssay Description:The human ether-a-go-go related gene (hERG) encodes the inward rectifying voltage gated potassium channel in the heart (Igr) which is involved in car...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50112245(CHEMBL3608741 | US10030025, Compound 11 | US108367...)
Affinity DataIC50:  5.00E+4nMAssay Description:The human ether-a-go-go related gene (hERG) encodes the inward rectifying voltage gated potassium channel in the heart (IKr) which is involved in car...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeuromedin-K receptor(Homo sapiens (Human))
Ogeda

US Patent
LigandPNGBDBM50112245(CHEMBL3608741 | US10030025, Compound 11 | US108367...)
Affinity DataIC50:  73nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
In DepthDetails US Patent